NAD+ and Diabetic Neuropathy: What a Terminated Pilot Trial Actually Found

Written by the Nuvirox Research Team

Short answer: promising in mice, but the one human pilot trial designed to test this directly didn't find a significant effect and was stopped before moving forward. This is one of the more instructive topics in NAD+ research, because it shows the full pipeline — strong preclinical data, a real human trial attempt, and a null result — rather than stopping at the hopeful mouse study, which is where a lot of supplement marketing tends to stop.

Why NAD+ was a reasonable candidate for diabetic neuropathy

Diabetic peripheral neuropathy — nerve damage caused by prolonged high blood sugar — involves oxidative stress and mitochondrial dysfunction in the long nerve fibers that run to the hands and feet, which are especially vulnerable because of their length and metabolic demands. NAD+ is central to both mitochondrial energy production and cellular defenses against oxidative stress, making it a scientifically reasonable target for researchers studying ways to protect or restore nerve function in diabetes.

What the mouse research found

A 2016 study published in Scientific Reports tested nicotinamide riboside in mouse models of prediabetes and type 2 diabetes with peripheral neuropathy. NR improved glucose tolerance, reduced weight gain and liver damage in prediabetic mice, and — critically for this topic — protected against the nerve damage measured in both models. Intraepidermal nerve fiber density (a direct, quantifiable measure of small nerve fiber health) was significantly preserved in NR-treated mice compared to untreated animals, and thermal sensitivity (a functional nerve test) was also better preserved. This was a genuinely strong, well-designed animal study, which is exactly why it justified moving on to human testing.

The human trial: NiRiD, and why it was stopped

Based on that preclinical foundation, researchers at the University of Maryland launched NiRiD (NCT03685253), a randomized, triple-masked pilot trial of nicotinamide riboside (1,000 mg/day) versus placebo in people with type 2 diabetes or impaired glucose tolerance and early diabetic neuropathy. The trial used intraepidermal nerve fiber density via skin biopsy as its primary outcome — the same rigorous, quantifiable measure used successfully in the mouse study — over six months of treatment. According to the trial registry, the study was completed as a pilot but terminated before advancing further, with the listed reason stating plainly that the pilot study did not show statistical significance in either its primary or secondary outcome measures, and that grant funding was not obtained to continue to a larger phase 2 study.

Why this result deserves to be front and center, not buried

It would be easy to write this article citing only the promising mouse data and describing the human trial vaguely as "ongoing" or "investigational" — some marketing content does exactly that. But the actual registry status is unambiguous: the pilot trial concluded without a statistically significant finding, and the research program didn't secure funding to continue. That's a meaningful, specific negative result from real human testing, using the gold-standard outcome measure for this condition, and it belongs at the center of this article rather than a footnote.

What actually has evidence for diabetic neuropathy

Tight blood sugar control remains the single most evidence-backed way to slow the progression of diabetic neuropathy — this is well established across decades of diabetes research. For neuropathic pain itself, medications like certain anticonvulsants (gabapentin, pregabalin) and certain antidepressants (duloxetine) have solid randomized trial support, prescribed and managed by a doctor. Alpha-lipoic acid has some supportive trial evidence specifically for diabetic neuropathy symptoms, though results are mixed and it should be discussed with a physician, particularly regarding interactions with diabetes medications.

What NAD+ won't do

Based on the actual pilot trial result, an NAD+ precursor should not be relied on to treat or reverse diabetic neuropathy. If you have diabetes and are noticing numbness, tingling, or pain in your feet or hands, that needs evaluation by your doctor — early detection and blood sugar management matter, and this isn't a place to substitute a supplement for medical care.

Why pilot trials matter even when they're negative

It's worth appreciating what the NiRiD pilot accomplished even though it didn't find a benefit: it used a rigorous, objective measure (skin biopsy nerve fiber density) rather than relying only on self-reported symptoms, which are more easily influenced by placebo response. A negative result from a well-designed pilot using an objective outcome is genuinely more informative than a positive result from an uncontrolled or subjectively measured study would have been. This is part of why the trial registry — not marketing summaries of the underlying mouse research — is the right place to look when evaluating whether an NAD+ precursor claim for a specific condition has actually been tested in people.

Frequently asked questions

Did the human trial show NAD+ makes neuropathy worse?

No — it showed no statistically significant effect in either direction on the primary or secondary outcomes measured. The trial was stopped due to the null pilot result and lack of continued funding, not due to safety concerns.

Why did something that worked in mice not work in the human pilot?

This happens often in medical research — mouse models don't always predict human results, dosing that's effective in mice doesn't always translate directly to an equivalent human dose, and a small pilot trial may simply be underpowered to detect a real but modest effect. It's also possible the effect genuinely doesn't hold up in humans; the pilot data alone can't distinguish between these explanations.

What's the best thing I can do to protect my nerves if I have diabetes?

Consistent blood sugar management is the best-evidenced approach for slowing neuropathy progression. Regular foot checks, working with your doctor on your A1C targets, and managing other cardiovascular risk factors also matter.

Is there ongoing research on this topic?

The specific NiRiD trial was not continued past its pilot phase due to funding, but NAD+ metabolism in neuropathy remains an active area of broader research interest, so this could change with future studies.

The bottom line

NAD+ and diabetic neuropathy is a rare case where the full research pipeline played out: a strong mouse study, a well-designed human pilot trial using a rigorous outcome measure, and a null result that ended the program before it reached a larger trial. That's useful, honest information — and it means diabetic neuropathy management should stay focused on blood sugar control and doctor-prescribed treatments rather than an NAD+ supplement. Related reading: NAD+ and metabolism and NAD+ and exercise recovery.

References

1. Trammell SAJ, Weidemann BJ, Chadda A, et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep. 2016;6:26933. PMC4882590.
2. Nicotinamide Riboside for Diabetic Neuropathy (NiRiD). ClinicalTrials.gov Identifier: NCT03685253. Status: terminated — pilot study did not show statistical significance.
3. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. PMID: 27999003.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.